GoodRx: Q1 And Q2 2026 Financial Statements Should Not Be Relied Upon - SEC Filing
Nov 2 (Reuters) - GoodRx Holdings, Inc. GDRX.O:
GOODRX - Q1 AND Q2 2026 FINANCIAL STATEMENTS SHOULD NOT BE RELIED UPON - SEC FILING
GOODRX - EXPECTS MATERIAL WEAKNESSES IN INTERNAL CONTROL FOR Q1 AND Q2 2026 - SEC FILING
Source text: [ID:n0001809519-26-000184]
Further company coverage: GDRX.O